JP2023544476A - Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物 - Google Patents

Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物 Download PDF

Info

Publication number
JP2023544476A
JP2023544476A JP2023510342A JP2023510342A JP2023544476A JP 2023544476 A JP2023544476 A JP 2023544476A JP 2023510342 A JP2023510342 A JP 2023510342A JP 2023510342 A JP2023510342 A JP 2023510342A JP 2023544476 A JP2023544476 A JP 2023544476A
Authority
JP
Japan
Prior art keywords
compound according
alkyl
cycloalkyl
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023510342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023544476A5 (enExample
Inventor
ホンチャン チャン
ピン チェン
チェンウェイ カイ
フェイ チャン
ペイファ サン
Original Assignee
ビバ スター バイオサイエンシズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビバ スター バイオサイエンシズ リミテッド filed Critical ビバ スター バイオサイエンシズ リミテッド
Publication of JP2023544476A publication Critical patent/JP2023544476A/ja
Publication of JP2023544476A5 publication Critical patent/JP2023544476A5/ja
Priority to JP2026020642A priority Critical patent/JP2026086696A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023510342A 2020-08-11 2021-10-09 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物 Pending JP2023544476A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026020642A JP2026086696A (ja) 2020-08-11 2026-02-12 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020108325 2020-08-11
CNPCT/CN2020/108325 2020-08-11
PCT/IB2021/059266 WO2022034568A1 (en) 2020-08-11 2021-10-09 Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026020642A Division JP2026086696A (ja) 2020-08-11 2026-02-12 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物

Publications (2)

Publication Number Publication Date
JP2023544476A true JP2023544476A (ja) 2023-10-24
JP2023544476A5 JP2023544476A5 (enExample) 2024-10-11

Family

ID=78179477

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023510342A Pending JP2023544476A (ja) 2020-08-11 2021-10-09 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物
JP2026020642A Pending JP2026086696A (ja) 2020-08-11 2026-02-12 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026020642A Pending JP2026086696A (ja) 2020-08-11 2026-02-12 Ｌｐａ受容体アンタゴニストとしてのトリアゾール－ピリジニル置換アザシクロヘキシル酢酸化合物

Country Status (9)

Country Link
EP (1) EP4196220A1 (enExample)
JP (2) JP2023544476A (enExample)
KR (1) KR20240068583A (enExample)
CN (1) CN116669727B (enExample)
AU (1) AU2021323515A1 (enExample)
CA (1) CA3191452A1 (enExample)
IL (1) IL300525A (enExample)
MX (1) MX2023001812A (enExample)
WO (1) WO2022034568A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
CN117751106A (zh) * 2021-04-30 2024-03-22 唯久生物技术(苏州)有限公司 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
WO2024022314A1 (zh) * 2022-07-25 2024-02-01 武汉人福创新药物研发中心有限公司 三氮唑类化合物及其作为lpar1拮抗剂的用途
CN121773091A (zh) * 2023-09-08 2026-03-31 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
WO2025162421A1 (zh) * 2024-02-04 2025-08-07 西藏海思科制药有限公司 Lpar1拮抗剂及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512178A (ja) * 2008-12-15 2012-05-31 パンミラ ファーマシューティカルズ，エルエルシー． リゾホスファチジン酸受容体のアンタゴニスト
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2016515536A (ja) * 2013-03-15 2016-05-30 エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. 疾患の治療に有用な複素環化合物
WO2019126098A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126093A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
WO2019126094A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as lpa antagonists
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
WO2020060915A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364659B1 (en) * 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
JP5931721B2 (ja) * 2009-06-16 2016-06-08 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ アシルＣｏＡリゾリン脂質アシルトランスフェラーゼの発現による長鎖オメガ−３及びオメガ−６多価不飽和脂肪酸生合成の改良
US8785442B2 (en) * 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
EP2922823B1 (en) 2012-11-20 2018-10-31 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
US20140200215A1 (en) * 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512178A (ja) * 2008-12-15 2012-05-31 パンミラ ファーマシューティカルズ，エルエルシー． リゾホスファチジン酸受容体のアンタゴニスト
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2016515536A (ja) * 2013-03-15 2016-05-30 エピゲン バイオサイエンシズ, インコーポレイテッドEpigen Biosciences, Inc. 疾患の治療に有用な複素環化合物
WO2019126098A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
WO2019126093A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
WO2019126094A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azoles as lpa antagonists
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
WO2020060915A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists

Also Published As

Publication number Publication date
IL300525A (en) 2023-04-01
AU2021323515A1 (en) 2023-03-09
CN116669727A (zh) 2023-08-29
WO2022034568A1 (en) 2022-02-17
KR20240068583A (ko) 2024-05-17
CN116669727B (zh) 2025-07-08
MX2023001812A (es) 2023-06-19
CA3191452A1 (en) 2022-02-17
EP4196220A1 (en) 2023-06-21
JP2026086696A (ja) 2026-05-26

Similar Documents

Publication Publication Date Title
CN116669727B (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
AU2017281439B2 (en) Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
JP6507216B2 (ja) ２−（モルホリン−４−イル）−１，７−ナフチリジン
JP6378759B2 (ja) Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
IL323675A (en) FGFR inhibitors and methods of using them
JP2025504486A (ja) Ｋｒａｓの標的分解のための化合物及び方法
CA3085561A1 (en) Cyclohexyl acid triazole azines as lpa antagonists
EP3886988A1 (en) 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2013066729A1 (en) Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
EA015488B1 (ru) Содержащие диариловый эфир соединения мочевины
EA038164B1 (ru) 3-замещенные пропановые кислоты в качестве ингибиторов интегрина v
JP2022517901A (ja) 環状尿素
JP2024517769A (ja) Ｌｐａアンタゴニストとしての新規トリアゾール－ピリジン置換ピロリジニル及びテトラヒドロ－２ｈ－ピラニル酢酸化合物
WO2024026483A2 (en) Cdk2 inhibitors and methods of using the same
AU2014234908A1 (en) N-(2-cyano heterocyclyl)pyrazolo pyridones as Janus kinase inhibitors
TW202435863A (zh) Cbl-b抑制劑
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
TW202430512A (zh) 類木瓜蛋白酶(PLpro)抑制劑
KR20240165360A (ko) 에모파밀 결합 단백질 억제제 및 이의 용도
KR20190070985A (ko) RORc 조절제로서의 피리다진 유도체
HK40100136A (zh) 作为lpa受体拮抗剂的三唑-吡啶基取代的氮杂环己基乙酸化合物
WO2026024373A2 (en) Cdk2 inhibitors for the treatment of cancer
WO2025062334A1 (en) 4-((5-(3-(4-(pyridin-2-yl)cyclopentyl)-1 h-pyrazol-3-yl)amino)-benzenesulfonamide derivatives and similar compounds as cdk inhibitors for the treatment of cancer
HK40102702A (en) Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250812

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260406

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260602

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260803